Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How could pharmacogenomics help improve patient survival?

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2007

Rosell Rafael, Felip Enriqueta, Paz-Ares Luis

Abstract excerpt

Increasing knowledge regarding multiple genetic disturbances found in human lung cancers, particularly non-small cell lung cancer (NSCLC), have enabled predictive markers to be used in specialised centres in tailoring chemotherapy regimens and improving survival and response in subgroups of patients. Impressive responses are observed in patients with epidermal growth factor receptor (EGFR) tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 Proteins
Share to Endonucleases
Share to Exonucleases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exoribonucleases

Share to Genes, BRCA1

Share to Pharmacogenetics

Share to Ribonucleoside Diphosphate Reductase

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 17686445
DOI: 10.1016/S0169-5002(07)70426-9

Genes

BRCA1
EGFR
ERCC1
RRM1
XRCC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How could pharmacogenomics help improve patient survival?PMID 17686445Read ↗

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Semantic proximity Read ↗

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.Semantic proximity Read ↗

Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.Semantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

Predicting the outcome of chemotherapy for lung cancer.Semantic proximity Read ↗

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.Semantic proximity Read ↗

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.Semantic proximity Read ↗

Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung CancerSemantic proximity Read ↗

From the bench to the bed: individualizing treatment in non-small-cell lung cancer.Semantic proximity Read ↗

Pharmacogenomic biomarkers for personalized cancer treatment.Semantic proximity Read ↗

Usefulness of predictive tests for cancer treatment.Semantic proximity Read ↗

Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.